Literature DB >> 21866321

The immune microenvironment of myeloma.

Kimberly Noonan1, Ivan Borrello.   

Abstract

The bone marrow (BM) is the site of disease in myeloma and possesses unique immune characteristics involved in the pathobiology of the disease. Interactions of plasma cells with stromal cells, osteoclasts, osteoblasts, myeloid and lymphoid cells make up the unique bone marrow milieu that mediates myeloma disease progression. Independently or through a complex network of interactions these cells impart immune changes leading to immune evasion and disease progression. The critical role of these factors in disease progression has led to the intense development of therapeutic strategies aimed at either disrupting the immune mechanisms mediating disease progression or augmenting those with anti-tumor benefits. This review discusses the major contributors of immunity in the bone marrow microenvironment, their interactions, and mechanisms whereby immune modulation can be translated into therapies with anti-myeloma efficacy.

Entities:  

Year:  2011        PMID: 21866321      PMCID: PMC3234331          DOI: 10.1007/s12307-011-0086-3

Source DB:  PubMed          Journal:  Cancer Microenviron        ISSN: 1875-2284


  119 in total

Review 1.  The Hedgehog and Wnt signalling pathways in cancer.

Authors:  J Taipale; P A Beachy
Journal:  Nature       Date:  2001-05-17       Impact factor: 49.962

Review 2.  NKT cells: what's in a name?

Authors:  Dale I Godfrey; H Robson MacDonald; Mitchell Kronenberg; Mark J Smyth; Luc Van Kaer
Journal:  Nat Rev Immunol       Date:  2004-03       Impact factor: 53.106

3.  Improving adoptive T cell therapy by targeting and controlling IL-12 expression to the tumor environment.

Authors:  Ling Zhang; Sid P Kerkar; Zhiya Yu; Zhili Zheng; Shicheng Yang; Nicholas P Restifo; Steven A Rosenberg; Richard A Morgan
Journal:  Mol Ther       Date:  2011-02-01       Impact factor: 11.454

4.  A bispecific antibody-IFNalpha2b immunocytokine targeting CD20 and HLA-DR is highly toxic to human lymphoma and multiple myeloma cells.

Authors:  Edmund A Rossi; Diane L Rossi; Rhona Stein; David M Goldenberg; Chien-Hsing Chang
Journal:  Cancer Res       Date:  2010-09-28       Impact factor: 12.701

5.  Knockdown of the interleukin-6 receptor alpha chain of dendritic cell vaccines enhances the therapeutic potential against IL-6 producing tumors.

Authors:  Wonchan Hwang; Keunok Jung; Youkyoung Jeon; Shik Yun; Tae Woo Kim; Inhak Choi
Journal:  Vaccine       Date:  2010-10-23       Impact factor: 3.641

Review 6.  Thalidomide: emerging role in cancer medicine.

Authors:  Paul Richardson; Teru Hideshima; Kenneth Anderson
Journal:  Annu Rev Med       Date:  2002       Impact factor: 13.739

7.  Dexamethasone synergizes with lenalidomide to inhibit multiple myeloma tumor growth, but reduces lenalidomide-induced immunomodulation of T and NK cell function.

Authors:  A K Gandhi; J Kang; L Capone; A Parton; L Wu; L H Zhang; D Mendy; A Lopez-Girona; T Tran; L Sapinoso; W Fang; S Xu; G Hampton; J B Bartlett; P Schafer
Journal:  Curr Cancer Drug Targets       Date:  2010-03       Impact factor: 3.428

8.  Increased circulating myeloid-derived suppressor cells correlate with clinical cancer stage, metastatic tumor burden, and doxorubicin-cyclophosphamide chemotherapy.

Authors:  C Marcela Diaz-Montero; Mohamed Labib Salem; Michael I Nishimura; Elizabeth Garrett-Mayer; David J Cole; Alberto J Montero
Journal:  Cancer Immunol Immunother       Date:  2008-04-30       Impact factor: 6.968

9.  Either interleukin-12 or interferon-gamma can correct the dendritic cell defect induced by transforming growth factor beta in patients with myeloma.

Authors:  Ross Brown; Allan Murray; Belinda Pope; Daniel M Sze; John Gibson; P Joy Ho; Derek Hart; Doug Joshua
Journal:  Br J Haematol       Date:  2004-06       Impact factor: 6.998

10.  Sustained expansion of NKT cells and antigen-specific T cells after injection of alpha-galactosyl-ceramide loaded mature dendritic cells in cancer patients.

Authors:  David H Chang; Keren Osman; John Connolly; Anjli Kukreja; Joseph Krasovsky; Maggi Pack; Aisha Hutchinson; Matthew Geller; Nancy Liu; Rebecca Annable; Jennifer Shay; Kelly Kirchhoff; Nobusuke Nishi; Yoshitaka Ando; Kunihiko Hayashi; Hani Hassoun; Ralph M Steinman; Madhav V Dhodapkar
Journal:  J Exp Med       Date:  2005-05-02       Impact factor: 14.307

View more
  21 in total

1.  Analysis of the immune system of multiple myeloma patients achieving long-term disease control by multidimensional flow cytometry.

Authors:  Roberto J Pessoa de Magalhães; María-Belén Vidriales; Bruno Paiva; Carlos Fernandez-Gimenez; Ramón García-Sanz; Maria-Victoria Mateos; Norma C Gutierrez; Quentin Lecrevisse; Juan F Blanco; Jose Hernández; Natalia de las Heras; Joaquin Martinez-Lopez; Monica Roig; Elaine Sobral Costa; Enrique M Ocio; Martin Perez-Andres; Angelo Maiolino; Marcio Nucci; Javier De La Rubia; Juan-Jose Lahuerta; Jesús F San-Miguel; Alberto Orfao
Journal:  Haematologica       Date:  2012-07-06       Impact factor: 9.941

Review 2.  MGUS to myeloma: a mysterious gammopathy of underexplored significance.

Authors:  Madhav V Dhodapkar
Journal:  Blood       Date:  2016-10-13       Impact factor: 22.113

Review 3.  The tumor microenvironment shapes hallmarks of mature B-cell malignancies.

Authors:  K H Shain; W S Dalton; J Tao
Journal:  Oncogene       Date:  2015-02-02       Impact factor: 9.867

Review 4.  Cellular and vaccine immunotherapy for multiple myeloma.

Authors:  Alfred L Garfall; Edward A Stadtmauer
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2016-12-02

Review 5.  Immunologic approaches for the treatment of multiple myeloma.

Authors:  Leo Rasche; Niels Weinhold; Gareth J Morgan; Frits van Rhee; Faith E Davies
Journal:  Cancer Treat Rev       Date:  2017-04-06       Impact factor: 12.111

Review 6.  CAR T cell therapy for multiple myeloma: where are we now and where are we headed?

Authors:  Arnab Ghosh; Sham Mailankody; Sergio A Giralt; C Ola Landgren; Eric L Smith; Renier J Brentjens
Journal:  Leuk Lymphoma       Date:  2017-11-06

7.  High expression of endoplasmic reticulum chaperone grp94 is a novel molecular hallmark of malignant plasma cells in multiple myeloma.

Authors:  Saurabh Chhabra; Sandeep Jain; Caroline Wallace; Feng Hong; Bei Liu
Journal:  J Hematol Oncol       Date:  2015-06-25       Impact factor: 17.388

8.  Relationship between abnormal osteoblasts and cellular immunity in multiple myeloma.

Authors:  Rong Fu; Shan Gao; Fengping Peng; Jing Li; Hui Liu; Huaquan Wang; Linmin Xing; Zonghong Shao
Journal:  Cancer Cell Int       Date:  2014-08-14       Impact factor: 5.722

Review 9.  The Role of Immunotherapy in Multiple Myeloma.

Authors:  Mehmet Kocoglu; Ashraf Badros
Journal:  Pharmaceuticals (Basel)       Date:  2016-01-14

10.  Th22 cells increase in poor prognosis multiple myeloma and promote tumor cell growth and survival.

Authors:  Giulia Di Lullo; Magda Marcatti; Silvia Heltai; Emanuela Brunetto; Cristina Tresoldi; Attilio Bondanza; Chiara Bonini; Maurilio Ponzoni; Giovanni Tonon; Fabio Ciceri; Claudio Bordignon; Maria Pia Protti
Journal:  Oncoimmunology       Date:  2015-02-03       Impact factor: 8.110

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.